ABBV vs BMY
ABBV and BMY side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABBVAbbVie Inc. | BMYBristol-Myers Squibb Company |
|---|---|---|
| Market cap | $449.07B | $124.44B |
| P/E (TTM) | 125.2 | 17.1 |
| P/B | — | 6.20 |
| P/S | 7.3x | 2.6x |
| Revenue | $61.16B(TTM) | $48.48B(TTM) |
| Revenue growth (YoY) | 8.6% | -0.2% |
| Net income | $3.63B(TTM) | $7.28B(TTM) |
| Earnings growth (YoY) | -1.2% | 178.8% |
| EPS, diluted | $2.03(TTM) | $3.57(TTM) |
| EBIT margin | 24.6% | 21.8% |
| ROE | — | 35.2% |
| ROIC | 20.0% | 14.4% |
| Piotroski F | — | 8/9 |
| 1y total return | +37.8% | +33.8% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: ABBV frente a BMY
| Métrica | ABBV | BMY |
|---|---|---|
| Valor final | $69.6K | $14.0K |
| Retorno total | +595.9% | +40.0% |
| CAGR | +20.6% | +3.3% |
| Volatilidad | 25.8% | 25.2% |
| Sharpe | 0.71 | 0.10 |
| Sortino | 0.99 | 0.14 |
| Caída máxima | -45.1% | -47.7% |
Basado en 2600 días de negociación comunes, 2016-03-16 → 2026-07-20 · tasa libre de riesgo 3.85% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)